Review



hba1c reduction  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MedChemExpress hba1c reduction
    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
    Hba1c Reduction, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hba1c reduction/product/MedChemExpress
    Average 90 stars, based on 7 article reviews
    hba1c reduction - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis"

    Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

    Journal: Endocrinology and Metabolism

    doi: 10.3803/EnM.2020.818

    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
    Figure Legend Snippet: Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

    Techniques Used: Control

    Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis
    Figure Legend Snippet: Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

    Techniques Used: Control, Modification, Transplantation Assay

    Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus
    Figure Legend Snippet: Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

    Techniques Used: Control

    Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.
    Figure Legend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

    Techniques Used: Control, Standard Deviation

    Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.
    Figure Legend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

    Techniques Used: Control, Standard Deviation



    Similar Products

    hba1c reduction  (MedChemExpress)
    90
    MedChemExpress hba1c reduction
    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
    Hba1c Reduction, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hba1c reduction/product/MedChemExpress
    Average 90 stars, based on 1 article reviews
    hba1c reduction - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    reduction hba1c  (Dexcom Inc)
    90
    Dexcom Inc reduction hba1c
    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
    Reduction Hba1c, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/reduction hba1c/product/Dexcom Inc
    Average 90 stars, based on 1 article reviews
    reduction hba1c - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    hba1c reduction since first attendance (ifcc)  (International Federation of Clinical Chemistry and Laboratory Medicine)
    90
    International Federation of Clinical Chemistry and Laboratory Medicine hba1c reduction since first attendance (ifcc)
    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
    Hba1c Reduction Since First Attendance (Ifcc), supplied by International Federation of Clinical Chemistry and Laboratory Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hba1c reduction since first attendance (ifcc)/product/International Federation of Clinical Chemistry and Laboratory Medicine
    Average 90 stars, based on 1 article reviews
    hba1c reduction since first attendance (ifcc) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    hba1c reduction  (Virta Labs)
    90
    Virta Labs hba1c reduction
    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus
    Hba1c Reduction, supplied by Virta Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hba1c reduction/product/Virta Labs
    Average 90 stars, based on 1 article reviews
    hba1c reduction - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mean reduction hba1c  (Ziemer USA Inc)
    90
    Ziemer USA Inc mean reduction hba1c
    Reminders and Process / Outcome Measures a
    Mean Reduction Hba1c, supplied by Ziemer USA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mean reduction hba1c/product/Ziemer USA Inc
    Average 90 stars, based on 1 article reviews
    mean reduction hba1c - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

    Journal: Endocrinology and Metabolism

    Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

    doi: 10.3803/EnM.2020.818

    Figure Lengend Snippet: Characteristics of Patients in the Randomised Controlled Trials Evaluated in this Meta-Analysis on the Use of Gemigliptin in Type 2 Diabetes Mellitus

    Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

    Techniques: Control

    Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

    Journal: Endocrinology and Metabolism

    Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

    doi: 10.3803/EnM.2020.818

    Figure Lengend Snippet: Characteristics of Patients in the Studies Evaluated for, but Excluded from, This Meta-Analysis

    Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

    Techniques: Control, Modification, Transplantation Assay

    Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

    Journal: Endocrinology and Metabolism

    Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

    doi: 10.3803/EnM.2020.818

    Figure Lengend Snippet: Summary of Findings: Gemigliptin Compared to Control in the Management of Type 2 Diabetes Mellitus

    Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

    Techniques: Control

    Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

    Journal: Endocrinology and Metabolism

    Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

    doi: 10.3803/EnM.2020.818

    Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the active control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

    Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

    Techniques: Control, Standard Deviation

    Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

    Journal: Endocrinology and Metabolism

    Article Title: Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis

    doi: 10.3803/EnM.2020.818

    Figure Lengend Snippet: Forest plot highlighting the impact of gemigliptin as compared to the passive control group after 24 weeks of therapy on (A) haemoglobin A1c (HbA1c), (B) fasting glucose, (C) the percent of people achieving HbA1c <7%, (D) the percent of people achieving HbA1c less than 6.5%. SD, standard deviation; IV, inverse variance; CI, confidence interval; M-H, Mantel-Haenszel.

    Article Snippet: HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], −0.06 to 0.23; P =0.24; I 2 =0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, −0.91%; 95% CI, −1.18 to −0.63); P <0.01; I 2 =89%; high certainty of evidence [HCE]).

    Techniques: Control, Standard Deviation

    Reminders and Process / Outcome Measures a

    Journal: Journal of Diabetes Science and Technology

    Article Title: Computerized Prompting and Feedback of Diabetes Care: A Review of the Literature

    doi:

    Figure Lengend Snippet: Reminders and Process / Outcome Measures a

    Article Snippet: Outcome : HbA1c < 7.0% (NS); mean HbA1c (NS); mean reduction HbA1c (NS); LDL < 100 mg/dl (NS); mean LDL cholesterol (NS); mean reduction LDL cholesterol (NS); blood pressure < 130/85 mmHg (NS); mean systolic blood pressure (NS); mean diastolic blood pressure (NS) Ziemer et al . (2006) 26 glucose levels, HbA1c, weight, blood pressure, use of medications Process : therapy intensification in response to glucose level (NS) Open in a separate window a LDL, low-density lipoprotein; NCQA, National Committee for Quality Assurance; NS, not significant Reminders and Process / Outcome Measures a Process and Outcome Measures Fifty processes and 57 outcomes were measured in the 15 studies ( ).

    Techniques: Control, Medications